NRIX

Rating neutralAI Memo

Nurix Therapeutics

As of 2026-05-05/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-05 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Mid-2026 Phase 3 bexobrutideg trial start • 2026-06-30

Expected move: +3%

Biggest risk

The bear case is that revenue fell to $6.3 million from $18.5 million as Sanofi collaboration revenue stepped down, R&D rose to $84.1 million, and Nurix explicitly said existing cash is not sufficient to fund clinical development through commercialization, leaving future financing and execution risk material [#8-K-2026-04-08] [#10-Q-2026-04-08].

Invalidation

Break below $10 or thesis failure.

What would change my mind?

The bull case is that Nurix now has a clearer registrational path around bexobrutideg, with an ongoing pivotal Phase 2 study designed to support potential Accelerated Approval and a planned confirmatory Phase 3 start by mid-2026, while the balance sheet still showed $540.7 million at February 28, 2026 [#8-K-2026-04-08] [#10-Q-2026-04-08].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-05

Base target

$18

p=45%

Bull target

$26

p=30%

Bear target

$10

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Immunology expansion via 2026 IND target
The bull case is that Nurix now has a clearer registrational path around bexobrutideg, with an ongoing pivotal Phase 2 study designed to support potential Accelerated Approval and a planned confirmatory Phase 3 start by mid-2026, while the balance sheet still showed $540.7 million at February 28, 2026 [#8-K-2026-04-08] [#10-Q-2026-04-08].
The packet shows a $30.0 median analyst target versus a $16.93 anchor price, but analyst target count is unavailable, so the apparent upside should be treated cautiously rather than as strong consensus validation.

BearKey bullets

Execution risk around enrollment, data quality, and timing is significant for a company whose equity story is concentrated in bexobrutideg milestones and partner-program progress.
Funding risk remains material beyond the next year: the 10-Q says existing cash should support operations for at least 12 months, but not completion of clinical trials through commercialization [#10-Q-2026-04-08].
High cash burn and widening losses: Q1 FY2026 net loss was $87.2 million, and R&D increased as Nurix accelerated Phase 2 enrollment and prepared for Phase 3 [#8-K-2026-04-08].

WatchKey bullets

Mid-2026 Phase 3 bexobrutideg trial start

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $18 (p=45%)

Bull/Bear spread: +48% / -43%

Vs latest close: Bull +48% · Base +3% · Bear -43%

Scenario probabilities

Bull Target: $26 (p=30%)Base Target: $18 (p=45%)Bear Target: $10 (p=25%)

Commentary

Primary-source tone is constructive on pipeline progress but not cleanly bullish on fundamentals: the April 8 update highlighted multiple 2026 catalysts and a sizable cash balance, yet revenue declined, spending rose, and the 10-Q kept the long-term funding gap explicit [#8-K-2026-04-08] [#10-Q-2026-04-08]. Recent media coverage in the packet is thin and mostly non-primary, with no robust analyst-revision set attached, so this remains a cautious monitoring view. Deterministic scoring also leans neutral with modestly negative forward returns and only mid-level evidence quality.

As of 2026-05-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Immunology expansion via 2026 IND target

Scenarios

Bull Target (Scenario probability)

$26 / p=30% prob

Base Target (Scenario probability)

$18 / p=45% prob

Bear Target (Scenario probability)

$10 / p=25% prob

Price $18 as of 2026-06-18

Nearest Scenario: Base (∆ 3%)

Targets vs latest close: Bull +48% · Base +3% · Bear -43%

Sentiment & Exposure

News Sentiment (30d)

52.00

Social Sentiment (7d)

50.00

Events

Other notable items detected

EVENT2026-06-30
Mid-2026 Phase 3 bexobrutideg trial start
Nurix said it plans to initiate the global randomized DAYBreak CLL-306 confirmatory Phase 3 trial by midyear 2026 to support full approval for bexobrutideg in relapsed/refractory CLL, making trial-start execution the clearest near-term pipeline checkpoint [#8-K-2026-04-08].
Prob 65.00% • Move 20.00% • Priced-in 35.00%
EVENT2026-09-30
2026 clinical data flow from NX-5948-301
Nurix said updated data from the NX-5948-301 Phase 1a/1b study are anticipated at upcoming medical meetings throughout 2026; positive efficacy or tolerability updates could improve confidence in earlier-line CLL positioning, while muted data would likely pressure sentiment [#8-K-2026-04-08].
Prob 55.00% • Move 22.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Immunology expansion via 2026 IND target
2026-12-31
Management is targeting a 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications using a new tablet formulation, which could broaden the platform beyond oncology if the healthy-volunteer work supports filing [#8-K-2026-04-08].
Prob 50% • Move 25% • Priced-in 25%

Risks

Execution risk around enrollment, data quality, and timing is significant for a company whose equity story is concentrated in bexobrutideg milestones and partner-program progress.
Funding risk remains material beyond the next year: the 10-Q says existing cash should support operations for at least 12 months, but not completion of clinical trials through commercialization [#10-Q-2026-04-08].
High cash burn and widening losses: Q1 FY2026 net loss was $87.2 million, and R&D increased as Nurix accelerated Phase 2 enrollment and prepared for Phase 3 [#8-K-2026-04-08].
Regulatory and trial-design risk is elevated because the Accelerated Approval strategy may require confirmatory work to be underway and FDA could still require additional studies or reject the proposed path [#10-Q-2026-04-08].

Peers

Symbol	Summary
CLDX	Celldex is the closest market-cap clinical-stage biotech comparator in the candidate set: valuation is also heavily event-driven by trial updates and regulatory path clarity rather than current product revenue.
MNKD	MannKind is a looser peer, but still useful as a small-cap biotech comparator for financing sensitivity and execution risk when commercial cash generation is limited relative to development needs.
GILD	Gilead is not a direct valuation peer, but it matters as a strategic collaboration benchmark because Nurix cited ongoing advancement of the partnered IRAK4 degrader and future milestone potential.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-05

AI Stock Memo: NRIX - Nurix Therapeutics - RankAlpha